Shots:
Myocardial infarction (MI), colloquially known as a heart attack, occurs when blood flow to the heart is severely reduced or blocked, causing tissue damage or mortality due to lack of oxygen
PharmaShots' Disease of the Month report aims to familiarize the general population with conditions impacting communities worldwide. The report outlines disease characteristics, types,…
Shots:
PharmaShots’ Designation Report provides a concise overview of the latest drug designations granted by major regulatory authorities, including the FDA, EMA, MHLW, and NMPA
The March 2025 report covers designations granted to 37 drugs and 3 medical devices, spanning 11 small molecules, 10 biologics, 10 cell and gene therapies & 3 medical devices among…
Jayasree K. Iyer, CEO of Access to Medicine Foundation, moderated a panel discussion that featured leaders from the 2024 Access to Medicine Index. Jayasree highlighted how biopharma companies foster accessibility to essential medicines in low- and middle-income countries through global partnerships, innovation, and sustainable models.
Jayasree talks about the future of Health Equity amidst the…
Predicting 2025 Trends: Jesse Mendelsohn from Model N in an Illuminating Discussion with PharmaShots
Shots:
Several undulating factors coalesce to inadvertently shape the biopharma industry
Prominent challenges include mounting pressure on Pharmacy Benefit Managers from independent pharmacies and drug manufacturers, a growing shortage of GLP-1 drugs, and the addition of 15 more drugs to the Inflation Reduction Act’s price negotiation list.
Jesse Mendelsohn, SVP at Model N, emphasizes the…
Shots:
Precision medicine holds a promising foothold in addressing unmet healthcare needs and bridging the gaps in care accessibility and high treatment costs
Defying the one-size-fits-all model, personalized medicine offers therapies tailored to an individual’s physiology, lifestyle, and environment
With this article, let’s capture the intricacies of precision medicine by navigating the benefits, challenges, progress,…
Shots:
The EMA’s CHMP has granted positive opinions and approvals to 2 Biologics and 1 New Chemical Entity in March 2025, leading to treatments for patients and advances in the healthcare industry
The major highlighted drugs were Merck’s Capvaxive to treat invasive pneumococcal disease
PharmaShots has compiled a list of 3 drugs that have been…
Shots:
PharmaShots has compiled a list of US FDA-approved drugs in the month of March 2025
The US FDA has approved a total of 2 new drug including 2 new molecular entities leading to the treatment of patients and advances in the healthcare industry
The major highlighted drug was GSK’s Blujepa securing approval for treating…
In the CXO Talks podcast, PharmaShots spoke with Ali Jannati, Director of Cognitive Science at Linus Health. Ali eloquently highlighted Linus’ journey to becoming a leader in digital brain health through its innovative digital cognitive assessment platform
He emphasized the importance of digital biomarkers in evaluating brain function by capturing subtle nuances and response latencies,…
PharmaShots is pleased to announce a new strategic data partnership with AlphaSense, marking an important milestone in our mission to elevate the quality, accessibility, and impact of insights across the biopharma and healthcare ecosystem.
This collaboration strengthens our commitment to reimagining intelligence and delivering unmatched industry updates that empower researchers, students, analysts, and biopharma professionals worldwide. By…
Emerging technologies holds a promising foothold in redefining the aspects of preventative, diagnostic, therapeutic, and patient care in the healthcare landscape. 3D Bioprinting offers innovative approach to addressing unmet healthcare needs with efficacious precision medicine in life-threatening conditions and developing therapies and medical devices that mimic complex human physiology.
In April, PharmaShots Magazine is exploring…

